亚宝药业(600351)近日披露的一则研发项目终止临床试验并计提减值准备的公告,让投资者猝不及防。回溯过往,这已经是近一年多以来,亚宝药业在创新药研发方面的第二次失利。 11月13日晚间,亚宝药业披露公告称,公司决定终止SY-005注射液用于脓毒症适应症项目的临床研究开发工作。据悉,SY-005注射液为一种创新型的重组蛋白,是亚宝药业在创新药研发领域的重点布局之一。 据悉,亚宝药业下属...
Source Link亚宝药业(600351)近日披露的一则研发项目终止临床试验并计提减值准备的公告,让投资者猝不及防。回溯过往,这已经是近一年多以来,亚宝药业在创新药研发方面的第二次失利。 11月13日晚间,亚宝药业披露公告称,公司决定终止SY-005注射液用于脓毒症适应症项目的临床研究开发工作。据悉,SY-005注射液为一种创新型的重组蛋白,是亚宝药业在创新药研发领域的重点布局之一。 据悉,亚宝药业下属...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.